BioPharma dealmaking is still going strong this summer. We're highlighting a few companies that caught our EyesOn team attention. Check out details on the Roche + Hanmi, Leo Pharma + Tanabe, and the SK BioPharma + Biohaven deals. By paying $190 million up front for a clinical-stage UCN2 (urocortin-2) analogue from South Korea’s Hanmi Pharm, Roche has advanced its obesity approach into unprecedented territory. Eli Lilly investigated the mechanism in a heart failure medicatio

We still have EyesOn Clinical Asset updates. This week we cover GSK's FDA approval for Jideytro, Royalty's ATTR deal, plus the Sanofi and Roche portfolio adjustments that include discontinuation of some assets.

We've been keeping EyesOn Strategic moves in the BioPharma space. Today we look at BioNTech's new CEO, Pfizer's continuing restructuring moves to remain competitive, and the reactions to a potential BMS + AZN merger.

We've had EyesOn recent clinical trial updates. Otsuka Pharma received approval for their ADHD therapy, Simtriyo, potentially a game changer for patients aged 6 and older. Meanwhile, Sanofi has stopped development of SAR445399, in bronchiectasis patients without cystic fibrosis as part of ther Portfolio re-alignment efforts.

This week we had EyesOn Merck KGaA and Sanofi and their corporate activities. Read about the antitrust proceedings against Sanofi and their Flu vaccine, and how the new CEO of Merck is changing their strategic direction with M&A.

This week we've had EyesOn clinical data and approvals for therapies in hematology and neurology. Check out the news onVertex's gene therapy approval for patients as young as 2-years old, Orca's allogeneic cell therapies approval for GVHD, and Ipsen's neurotoxin Phase 3 data showing efficacy in both episodic and chronic migraines.

This week we're sharing a couple of articles focused on competitive advantage in US BioPharma. Take a look at how the Oral GLP-1 market is shaping up, and the new US Initiative Operation TrialBlazer is trying to boost US Early-Stage Clinical Development Capabilities.

This week we've had EyesOn all the recent Business Development activities in the BioPharma world. We're sharing a few that caught our eye. Check out AbbVie's acquisition of Apogee to strengthen out their I&I portfolio, Sangamo's asset sale, and Pfizer's recent clinical results from one of their Seagen candidates.

Although GSK and Takeda are facing very different circumstances, both companies are flexing their Risk management skills to remain competitive.

Three recent clinical updates illustrate the opportunities and challenges facing next-generation oncology therapies. ADC Therapeutics reported positive efficacy data for Zynlonta...

EyesOn Strategic Agility in Action: How Biopharma Companies Are Managing Clinical, Commercial, and Operational Levers to Sustain Growth

Clinical Data Drives Strategic Decisions: Oruka, Boehringer, and Astellas Navigate Risk and Opportunity. Recent trial readouts highlight how clinical outcomes—positive and negative—are shaping portfolio decisions and competitive positioning.

From biosimilars scale to targeted oncology innovation, recent deals highlight how companies are using acquisition to accelerate positioning across key therapeutic and market opportunities.

ADC Arms Race Accelerates: Lilly and Gilead Double Down on Next-Generation Oncology Platforms. Acquisitions of CrossBridge and Tubulis highlight how antibody-drug conjugates are becoming a central pillar of oncology pipeline strategy.

Strategic Reallocation in Action: Takeda, Daiichi Sankyo, and Shionogi refocus for Growth and Market Access. Portfolio exits, capital shifts, and U.S. manufacturing expansion highlight how companies are actively adjusting strategic levers.

Strong clinical performance remains essential—but sustained commercial success increasingly depends on how effectively companies align pricing, access, targeting, and competitive positioning

From oral biologics to next-generation RNA therapies, companies are investing heavily in platforms that redefine how medicines are delivered and where they act.

From workforce reductions to manufacturing bottlenecks and regulatory divergence, structural pressures are reshaping how pharma operates.

Korsana Biosciences raised $175 million to develop next-generation Alzheimer’s antibodies. Its lead candidate uses transferrin receptor targeting to cross the blood-brain barrier. The company plans to enter clinical trials in 2027. Several competitors are pursuing similar delivery strategies.

The week we've had Eyes on the Ocular Therapeutix phase 3 SOL-1 data showing superiority over Eylea in wet AMD. The trial showed improved visual acuity preservation, The program could introduce the first tyrosine kinase inhibitor therapy for wet AMD however, investors reacted cautiously to the news.